Kangstem Biotech Co. Ltd Total Assets
Kangstem Biotech Co. Ltd total assets. Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) holds total assets worth ₩68.42 Billion KRW (≈ $46.37 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 217730 market cap for the company's overall valuation and market capitalisation.
Total Assets of Kangstem Biotech Co. Ltd (2015–2025)
Total assets of Kangstem Biotech Co. Ltd from 2015 to 2025. This chart illustrates how Kangstem Biotech Co. Ltd's total assets have evolved over time, based on quarterly financial data. See 217730 stock price and chart for real-time trading data and today's change.
Kangstem Biotech Co. Ltd - Asset Composition Analysis
Kangstem Biotech Co. Ltd Total Assets Breakdown (December 2025)
Kangstem Biotech Co. Ltd total assets breakdown as of December 2025. Kangstem Biotech Co. Ltd's total assets of ₩68.42 Billion consist of 53.5% current assets and 46.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.4% |
| Accounts Receivable | ₩438.78 Million | 0.5% |
| Inventory | ₩814.51 Million | 1.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩9.21 Billion | 11.3% |
| Goodwill | ₩7.26 Billion | 8.9% |
Asset Composition Trend (2015–2025)
This chart illustrates how Kangstem Biotech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 217730 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kangstem Biotech Co. Ltd's current assets represent 53.5% of total assets in 2025, a decrease from 75.6% in 2015.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, down from 20.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 3.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Kangstem Biotech Co. Ltd Competitors by Total Assets
Key competitors of Kangstem Biotech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Kangstem Biotech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.96 | 2.73 | 2.08 |
| Quick Ratio | 3.83 | 2.62 | 2.05 |
| Cash Ratio | 0.00 | 0.00 | 0.39 |
| Working Capital | ₩23.46 Billion | ₩11.07 Billion | ₩19.92 Billion |
Kangstem Biotech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Kangstem Biotech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 45.6% |
| Total Assets | ₩81.49 Billion |
| Market Capitalization | $119.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kangstem Biotech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kangstem Biotech Co. Ltd's assets grew by 45.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kangstem Biotech Co. Ltd (2015–2025)
The table below shows the annual total assets of Kangstem Biotech Co. Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩81.49 Billion ≈ $55.23 Million |
+45.56% |
| 2024-12-31 | ₩55.99 Billion ≈ $37.94 Million |
-31.10% |
| 2023-12-31 | ₩81.25 Billion ≈ $55.06 Million |
+0.82% |
| 2022-12-31 | ₩80.59 Billion ≈ $54.62 Million |
-21.87% |
| 2021-12-31 | ₩103.15 Billion ≈ $69.90 Million |
+25.02% |
| 2020-12-31 | ₩82.51 Billion ≈ $55.91 Million |
-27.40% |
| 2019-12-31 | ₩113.64 Billion ≈ $77.01 Million |
+55.26% |
| 2018-12-31 | ₩73.19 Billion ≈ $49.60 Million |
+59.42% |
| 2017-12-31 | ₩45.91 Billion ≈ $31.12 Million |
-3.22% |
| 2016-12-31 | ₩47.44 Billion ≈ $32.15 Million |
+89.90% |
| 2015-12-31 | ₩24.98 Billion ≈ $16.93 Million |
-- |
About Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more